Literature DB >> 29368793

Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.

Ziwei Liao1,2, Xuewen Lv1, Sichu Liu3, Zifan He1, Shaohua Chen1, Liang Wang4, Wenyu Li2, Yangqiu Li1,2.   

Abstract

AIM: To better understand the T-cell immunodeficiency status in patients with peripheral T-cell lymphomas (PTCLs) and NK/T-cell lymphomas (NK/T-CLs), the T-cell inhibitory receptors expression pattern was investigated.
METHODS: The expression levels of programmed death 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), B/T lymphocyte attenuator (BTLA), lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin-3 (TIM-3), T-cell immunoglobulin and ITIM domain (TIGIT) genes were detected in peripheral blood mononuclear cells (PBMCs) from patients and healthy volunteers by quantitative real-time-PCR, the correlation between different gene expression levels was analyzed.
RESULTS: Significantly higher expression of PD-1, CTLA-4, BTLA, LAG-3, TIM-3 and TIGIT can be observed as a common characteristic in patients with PTCL or NK/T-CL. However, the coexpression pattern seemed different between subtypes. Their overexpression is also related to disease progression stage.
CONCLUSION: We first characterized the expression pattern of six T-cell inhibitory receptor genes in PTCL and NK/T-CL, which might work as immune biomarkers for evaluation the immunosuppression status and help to establish the precision targets of immunotherapy.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  BTLA; CTLA-4; LAG-3; NK/T-CL; PD-1; PTCL; TIGIT; TIM-3

Mesh:

Substances:

Year:  2018        PMID: 29368793     DOI: 10.1111/ajco.12850

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  6 in total

1.  Immunomodulatory function of the active ingredients in traditional Chinese prescriptions on early stage esophageal cancer with dysplasia.

Authors:  Wenbo Jiang; Ning Qin; Tao Chen; Junwei Xu
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Lower T cell inhibitory receptor level in mononuclear cells from cord blood compared with peripheral blood.

Authors:  Ying Lin; Jinrong Lin; Jingying Huang; Youchun Chen; Jiaxiong Tan; Yangqiu Li; Shaohua Chen
Journal:  Stem Cell Investig       Date:  2019-10-21

3.  Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.

Authors:  F Solorzano-Ibarra; A G Alejandre-Gonzalez; P C Ortiz-Lazareno; B E Bastidas-Ramirez; A Zepeda-Moreno; M C Tellez-Bañuelos; N Banu; O J Carrillo-Garibaldi; A Chavira-Alvarado; M R Bueno-Topete; S Del Toro-Arreola; J Haramati
Journal:  Clin Exp Immunol       Date:  2021-01-18       Impact factor: 5.732

Review 4.  Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.

Authors:  Teresa Poggio; Justus Duyster; Anna L Illert
Journal:  Cancers (Basel)       Date:  2018-09-18       Impact factor: 6.639

Review 5.  The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.

Authors:  Haoyu Sun; Cheng Sun
Journal:  Front Immunol       Date:  2019-10-17       Impact factor: 7.561

6.  High TRGV 9 Subfamily Expression Marks an Improved Overall Survival in Patients With Acute Myeloid Leukemia.

Authors:  Xueting Kong; Jiamian Zheng; Xiaxin Liu; Wandi Wang; Xuan Jiang; Jie Chen; Jing Lai; Zhenyi Jin; Xiuli Wu
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.